Defize I L, van der Horst S, Bülbul M, Haj Mohammad N, Mook S, Meijer G J, Brosens L A A, Ruurda J P, van Hillegersberg R
Department of Surgery, G04.228, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Ann Surg Oncol. 2021 May;28(5):2730-2738. doi: 10.1245/s10434-020-09425-2. Epub 2020 Dec 19.
Patients with esophageal cancer that invades adjacent structures (cT4b) are precluded from surgery and usually treated with definitive chemoradiotherapy (dCRT). dCRT might result in sufficient downstaging to enable a radical resection, possibly improving survival. This study aimed to assess the perioperative and oncologic outcomes of a salvage robot-assisted minimally invasive esophagectomy (RAMIE) in patients with cT4b esophageal cancer after dCRT.
Between June 2012 and November 2019, patients who underwent a RAMIE with a gastric conduit reconstruction after completion of dCRT for cT4b esophageal carcinoma were identified from a prospectively maintained surgical database at the University Medical Center Utrecht.
In total, 24 patients with a histopathologically confirmed T4b adenocarcinoma or squamous cell carcinoma of the esophagus were included. The adjacent organs involved were the tracheobronchial tree (67%), aorta (21%) or both (13%). No conversions or major intraoperative complications were observed. A radical resection was achieved in 22 patients (92%), and a pathologic complete response was observed in 13 (54%) patients. Postoperative grade 2 or higher complications occurred in 20 patients (83%). The disease-free survival at 24 months was 68% for the patients in whom a radical resection was achieved.
In patients with cT4b esophageal cancer treated with dCRT followed by a salvage RAMIE, a radical resection rate of 92% was achieved, with acceptable complications and promising survival rates. These results demonstrate the feasibility of a curative surgical treatment for patients with initially irresectable esophageal cancer but underscore the importance of a proper preoperative patient selection.
侵犯相邻结构的食管癌患者(cT4b)无法进行手术,通常采用根治性放化疗(dCRT)。dCRT可能会使肿瘤充分降期,从而能够进行根治性切除,有可能提高生存率。本研究旨在评估接受dCRT后的cT4b食管癌患者行挽救性机器人辅助微创食管切除术(RAMIE)的围手术期和肿瘤学结局。
2012年6月至2019年11月期间,从乌得勒支大学医学中心前瞻性维护的手术数据库中,识别出在完成cT4b食管癌的dCRT后接受了带胃管道重建的RAMIE的患者。
总共纳入了24例经组织病理学确诊为食管T4b腺癌或鳞状细胞癌的患者。受累的相邻器官为气管支气管树(67%)、主动脉(21%)或两者均受累(13%)。未观察到中转或严重术中并发症。22例患者(92%)实现了根治性切除,13例(54%)患者观察到病理完全缓解。20例患者(83%)发生了2级或更高等级的术后并发症。实现根治性切除的患者24个月无病生存率为68%。
对于接受dCRT后行挽救性RAMIE治疗的cT4b食管癌患者,根治性切除率达到92%,并发症可接受,生存率有前景。这些结果证明了对初始不可切除的食管癌患者进行根治性手术治疗的可行性,但强调了术前正确选择患者的重要性。